Gilead Sciences, Inc. $GILD Position Raised by Ameritas Advisory Services LLC

Ameritas Advisory Services LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,492 shares of the biopharmaceutical company’s stock after buying an additional 616 shares during the period. Ameritas Advisory Services LLC’s holdings in Gilead Sciences were worth $609,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GILD. Hilltop National Bank acquired a new position in shares of Gilead Sciences during the 2nd quarter valued at $86,000. Triad Wealth Partners LLC purchased a new stake in Gilead Sciences during the second quarter valued at about $205,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Gilead Sciences by 8.2% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 556,766 shares of the biopharmaceutical company’s stock worth $61,729,000 after purchasing an additional 42,128 shares during the period. Cornell Pochily Investment Advisors Inc. boosted its position in shares of Gilead Sciences by 24.8% in the second quarter. Cornell Pochily Investment Advisors Inc. now owns 11,812 shares of the biopharmaceutical company’s stock worth $1,310,000 after buying an additional 2,349 shares during the period. Finally, J2 Capital Management Inc grew its stake in Gilead Sciences by 58.9% during the 2nd quarter. J2 Capital Management Inc now owns 3,864 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 1,432 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, UBS Group increased their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the transaction, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 82,000 shares of company stock worth $9,402,130 in the last three months. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.9%

Shares of NASDAQ GILD opened at $112.69 on Monday. The stock has a market cap of $139.83 billion, a PE ratio of 22.45, a PEG ratio of 0.77 and a beta of 0.34. The business has a fifty day moving average of $114.34 and a two-hundred day moving average of $109.97. Gilead Sciences, Inc. has a 52-week low of $83.98 and a 52-week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.